3/26
10:27 am
blte
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $80.00 price target on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $80.00 price target on the stock.
3/18
09:19 am
blte
Belite Bio, Inc (NASDAQ: BLTE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/18
08:06 am
blte
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
3/17
06:07 am
blte
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/17
06:07 am
blte
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website [Yahoo! Finance]
Medium
Report
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website [Yahoo! Finance]
3/17
06:00 am
blte
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
Medium
Report
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
3/17
06:00 am
blte
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/11
03:00 am
blte
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
3/4
07:07 pm
blte
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Low
Report
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
3/4
08:00 am
blte
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
Medium
Report
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
2/27
02:55 am
blte
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects [Yahoo! Finance]
Medium
Report
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects [Yahoo! Finance]
2/27
02:00 am
blte
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
Medium
Report
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
2/5
10:35 pm
blte
Belite Bio Announces Registered Direct Offering of $15 Million
Medium
Report
Belite Bio Announces Registered Direct Offering of $15 Million
1/27
04:30 pm
blte
Belite Bio files for automatic mixed securities shelf [Seeking Alpha]
Medium
Report
Belite Bio files for automatic mixed securities shelf [Seeking Alpha]
1/23
05:31 pm
blte
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight
Low
Report
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight
1/23
05:31 pm
blte
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight
Low
Report
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight
1/21
11:51 am
blte
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Benchmark Co. from $57.00 to $79.00. They now have a "buy" rating on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Benchmark Co. from $57.00 to $79.00. They now have a "buy" rating on the stock.